Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

PHASE2RecruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Refractory AnginaCoronary Artery Disease
Interventions
COMBINATION_PRODUCT

XC001

XC001 administered by percutaneous catheter delivery using the Extroducer® Infusion Catheter System.

COMBINATION_PRODUCT

Sham (No Treatment)

Subjects randomized to the sham catheterization procedure group will receive the same procedure as the treatment group (with introduction of an iliofemoral or radial sheath, positioning of the pigtail catheter in the left ventricle, generation of ventriculograms, and mimicking of the injection procedure by the interventional team following a Cath Lab script), except they will not have the delivery catheter inserted and will not receive any endocardial injections

Trial Locations (1)

45219

RECRUITING

Christ Hospital, Cincinnati

All Listed Sponsors
lead

XyloCor Therapeutics, Inc.

INDUSTRY

NCT07048808 - Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. | Biotech Hunter | Biotech Hunter